Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
Systemic hypertension is the most common comorbidity among cancer patients. Cancer and hypertension have common risk factors, have overlapping pathophysiological mechanisms and hypertension may also be a risk factor for some tumor types. Monitoring and management of hypertension before, during, and after cancer treatment can be improved to minimize cardiovascular risks.

Related Post